Psorizide Ultra
Potassium Bromide, Nickel Sulfate, And Zinc Bromide
Plymouth Healthcare Products Llc
Human Prescription Drug
NDC 61480-124Psorizide Ultra also known as Potassium Bromide, Nickel Sulfate, And Zinc Bromide is a human prescription drug labeled by 'Plymouth Healthcare Products Llc'. National Drug Code (NDC) number for Psorizide Ultra is 61480-124. This drug is available in dosage form of Tablet. The names of the active, medicinal ingredients in Psorizide Ultra drug includes Nickel Sulfate - 1 [hp_X]/1 Potassium Bromide - 1 [hp_X]/1 Zinc Bromide - 4 [hp_X]/1 . The currest status of Psorizide Ultra drug is Active.
Drug Information:
| Drug NDC: | 61480-124 |
| The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC. |
| Proprietary Name: | Psorizide Ultra |
| Also known as the trade name. It is the name of the product chosen by the labeler. |
| Product Type: | Human Prescription Drug |
| Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing. |
| Non Proprietary Name: | Potassium Bromide, Nickel Sulfate, And Zinc Bromide |
| Also known as the generic name, this is usually the active ingredient(s) of the product. |
| Labeler Name: | Plymouth Healthcare Products Llc |
| Name of Company corresponding to the labeler code segment of the ProductNDC. |
| Dosage Form: | Tablet |
| The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources. |
| Status: | Active |
| FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved. |
| Substance Name: | NICKEL SULFATE - 1 [hp_X]/1
POTASSIUM BROMIDE - 1 [hp_X]/1
ZINC BROMIDE - 4 [hp_X]/1
|
| This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted. |
| Route Details: | ORAL
|
| The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. |
Marketing Information:
An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
| Marketing Category: | UNAPPROVED HOMEOPATHIC |
| Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. |
| Marketing Start Date: | 01 Oct, 1997 |
| This is the date that the labeler indicates was the start of its marketing of the drug product. |
| Marketing End Date: | 29 Dec, 2025 |
| This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached. |
| Listing Expiration Date: | 31 Dec, 2023 |
| This is the date when the listing record will expire if not updated or certified by the firm. |
OpenFDA Information:
An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
| Manufacturer Name: | PLYMOUTH HEALTHCARE PRODUCTS LLC
|
| Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC. |
| Original Packager: | Yes
|
| Whether or not the drug has been repackaged for distribution. |
| UPC: | 0361480124052
|
| UPC stands for Universal Product Code. |
| UNII: | 4FLT4T3WUN
OSD78555ZM
OO7ZBU9703
|
| Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information. |
| Pharmacologic Class: | Copper Absorption Inhibitor [EPC]
Decreased Copper Ion Absorption [PE]
|
| These are the reported pharmacological class categories corresponding to the SubstanceNames listed above. |
Packaging Information:
| Package NDC | Description | Marketing Start Date | Marketing End Date | Sample Available |
|---|
| 61480-124-05 | 100 TABLET in 1 BOTTLE (61480-124-05) | 01 Oct, 1997 | N/A | No |
| Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together. |
Product Elements:
Psorizide ultra potassium bromide, nickel sulfate, and zinc bromide lactose magnesium stearate potassium bromide bromide ion nickel sulfate nickel cation zinc bromide zinc cation off white with green speckles ll
Drug Interactions:
Drug interactions there are no known drug interactions.
Indications and Usage:
Indications psorizide ® ultra is indicated for the treatment of moderate to severe eczema, atopic dermatitis, seborrhea and seborrheic dermatitis. it has been found to work well with variety of combination therapies. psoriasis also responds, but generally has a more favorable response to psorizide ® forte (ndc 61480-255-05.)
Warnings:
Warning do not use if imprinted seal under bottle cap is missing or broken. do not use if pregnant or nursing. if allergic to nickel or metal objects such as jewelry or if there is a history of blistering hand eczema, see precautions for hypersensitivity information. lactose intolerant patients may have gastrointestinal difficulty. this has very rarely been reported at the doses used.
Dosage and Administration:
Dosage and administration absorption of nickel sulphate is variable among individuals. for maximum absorption, tablets should be taken orally at the beginning of the day (or any convenient time after having taken nothing but water for at least 7 hours). take nothing but water for one hour after taking medication to aid absorption. weight starting dose max. dose 50-100 lbs ½ tablet 1 tablet 100-150 lbs 1 tablet 2 tablets 150-200 lbs 2 tablets 4 tablets over 200 lbs 3 tablets 6 tablets in the setting of renal impairment, dosage should be adjusted and serum nickel and bromide levels should be followed. steady state trough level should be drawn prior to ingesting the day's dose after one week of dosing or at appropriate intervals. target trough serum nickel level is 20-40 mcg/l. (warning: post dose peak levels are unreliable.) treatment duration depends on the individual. increase dose as needed on a monthly basis. maintenance phase in order to maintain symptomatic relief, medication ma
Read more...y be continued at the same or reduced initial phase dose level.
Contraindications:
Contraindications although there are no known contraindications, patients who are allergic to any psorizide ® ultra ingredient should consult a physician prior to taking the medication. (refer to section on hypersensitivity )
Adverse Reactions:
Adverse reactions psorizide ® ultra contains low doses of active ingredients. therefore there are minimal known side effects. (see precautions for hypersensitivity information)
Drug Interactions:
Drug interactions there are no known drug interactions.
Use in Pregnancy:
Pregnancy pregnancy category c animal reproduction studies have not been conducted with psorizide ® ultra. psorizide ® ultra should not be given to a pregnant woman.
Pediatric Use:
Pediatric use carefully adjust dosage to weight when treating young children.
Overdosage:
Overdosage potassium bromide toxicity indications of toxicity due to oral overdosage of bromide may include nausea, vomiting, apathy, disturbed coordination, loss of memory, drowsiness, loss of emotional control, agitation, hallucination, tremors, depressed reflexes, stupor, and coma. acute toxic reactions in humans have been reported at doses as low as 1000 mg. 21 this level is 67 times the dose received in one tablet of psorizide ® ultra. nickel sulphate toxicity the oral rat ld 50 for nickel sulphate hexahydrate is 275 mg/kg. 19 symptoms of toxicity due to oral overdosage of nickel sulphate may include nausea, vomiting, abdominal discomfort, diarrhea, giddiness, lassitude, headaches, cough, and shortness of breath. 20 the lowest observed transitory toxic effects from human ingestion of soluble nickel salts is approximately 8 mg nickel/kg body weight. 20 this is 80 times the maximum dose recommended for psorizide ® ultra. (see below ).
Description:
Description psorizide ® ultra is a biochemical homeopathic medication indicated for the treatment of eczema and seborrhea . 24-26 the active ingredients in each psorizide ® ultra tablet consist of the following: potassium bromide (kali bromatum) 1x, nickel sulphate (niccolum sulphuricum) 1x and zinc bromide (zincum bromatum) 4x. these drug ingredients are listed in the homoeopathic pharmacopoeia of the united states (hpus). 1 inactive ingredients: lactose and magnesium stearate. pharmacological class: homeopathic drug dosage form: oral 300 mg scored tablet. may be swallowed whole, chewed or dissolved in the mouth and swallowed.
Clinical Pharmacology:
Clinical pharmacology the active ingredients in psorizide ® ultra are inorganic soluble mineral salts. the exact mechanism of action is unknown; however, it is believed psorizide ® ultra addresses a primary genetic biochemical defect. potassium bromide dissolves and dissociates in the digestive tract into its ionic constituents. each tablet contains approximately 15 mg bromide (calculated). ionic bromide is rapidly and completely absorbed from the intestine and distributed almost exclusively in the extracellular fluids. 7,8 bromide is eliminated by the kidneys and the elimination half-life is 11-12 days. "once a day" dosing will lead to a steady state concentration in about seven weeks. 7 nickel sulphate dissolves and dissociates in the digestive tract into its ionic constituents. each tablet contains approximately 1.5 mg of ionic nickel (calculated). according to studies, 15% to 50% of ionic nickel is absorbed on a fasted stomach. 2 food markedly decreases the rate and extent of
Read more... nickel absorption. 3,4 clinical studies show that serum concentrations of nickel are variable among patients after administering the same dosage. 5 peak serum nickel concentration is reached about two hours after oral administration. "once a day" dosing leads to steady state serum concentrations in approximately one week. nickel is in its highly stable divalent cation state and is therefore not expected to be metabolized to any significant degree in the body. absorbed nickel is primarily excreted in the urine and elimination half-life is about 21 hours. 3,5 renal clearance is rapid and efficient, and nickel does not accumulate in the body. 6
Carcinogenesis and Mutagenesis and Impairment of Fertility:
Carcinogenesis, mutagenesis, impairment of fertility no studies have been done on the carcinogenesis or mutagenesis, or impairment of fertility of psorizide ® ultra. no carcinogenesis or mutagenesis has been reported in multiple animal studies for oral administration of soluble nickel and bromide salts (active ingredients) even at very high doses. 10-16 effects of soluble potassium bromide kbr is not listed as a carcinogen by the ntp, iarc, and osha. 18 effects of soluble nickel sulphate studies on experimental animals have never indicated that nickel, at any dose, is a carcinogen when introduced to the body orally. furthermore, nickel sulphate and other highly water soluble nickel salts, have never been known to induce carcinogenesis via any route of introduction including: oral, inhalation, cutaneous, im, or ip. 10-12,17 no adverse effects were noted on fertility or reproduction in a 3-generational study of albino wistar rats fed up to 1000 ppm ni per day, which is equivalent to 5
Read more...0 mg/kg body weight per day ni. 17
Clinical Studies:
Clinical studies a variety of controlled clinical studies have been performed using various sources of both nickel and bromide in over 300 subjects. clinical efficacy and safety have been documented in a significant number of subjects. published and unpublished reports are available upon request. 9,22,23
How Supplied:
How supplied scored tablets, off white in color with green speckles, with ll and score imprinted on same side, in child-resistant and tamper-resistant bottles of 100. ndc 61480-124-05.
Information for Patients:
Information for patients patients using psorizide ® ultra should receive the following information and instructions: this medication is to be used as directed by a physician. it is important to take orally at the beginning of the day on an empty stomach (or any convenient time after having taken nothing but water for at least 7 hours) and to eat or drink nothing but water for at least one hour afterwards to avoid interference with absorption.
Package Label Principal Display Panel:
Principal display panel - 100 tablet bottle ndc 61480-124-05 homeopathic medication psorizide ® ultra indicated for treatment of eczema & seborrhea 100 tablets chemical structure